Literature DB >> 9371545

The phosphatidylinositol 3-kinase inhibitor wortmannin markedly reduces chemotactic peptide-induced locomotion and increases in cytoskeletal actin in human neutrophils.

V Niggli1, H Keller.   

Abstract

To define a possible role of the enzyme phosphatidylinositol 3-kinase (PI 3-kinase) in motile functions of neutrophils, we have used a potent inhibitor of this enzyme, [1S-(1alpha,6b alpha,9a beta,11alpha,11bbeta)]-1-(acetyloxy)-1,6b,7,8,9a,10,11 ,11b-octahydro-1-(methoxymethyl)-9a,11b-dimethyl-3H-furo[4,3,2-de]indeno [4,5-h]-2-benzopyran-3,6,9-trione (wortmannin). Wortmannin markedly attenuated chemotactic peptide-induced development of polarity, locomotion and increases in cytoskeletal actin and alpha-actinin in human neutrophils at low, nM, concentrations (ED50 = 4-40 nM; 0.4-3 pmol/10(6) cells). The increase in cytoskeletal actin induced by phorbol-12-myristate-13-acetate in contrast was not affected by wortmannin (18 pmol/10[6] cells). Moreover, the increase in total F-actin induced by an incubation for 1 min with chemotactic peptide was much less sensitive to wortmannin than increases in cytoskeletal actin; 80 pmol/10(6) cells were necessary for half-maximal inhibition. Wortmannin thus appears to primarily affect F-actin organization, rather than polymerization. Inhibition of development of polarity by wortmannin correlated with inhibition of production of phosphatidylinositol 3,4,5-trisphosphate. According to our findings, activation of a wortmannin-sensitive target, very likely PI 3-kinase, is required for optimal chemotactic peptide-induced neutrophil motility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371545     DOI: 10.1016/s0014-2999(97)01169-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  Leukocytes navigate by compass: roles of PI3Kgamma and its lipid products.

Authors:  P Rickert; O D Weiner; F Wang; H R Bourne; G Servant
Journal:  Trends Cell Biol       Date:  2000-11       Impact factor: 20.808

Review 2.  Regulation of cell polarity during eukaryotic chemotaxis: the chemotactic compass.

Authors:  Orion D Weiner
Journal:  Curr Opin Cell Biol       Date:  2002-04       Impact factor: 8.382

Review 3.  Understanding the structure and function of the immunological synapse.

Authors:  Michael L Dustin; Arup K Chakraborty; Andrey S Shaw
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-09-15       Impact factor: 10.005

4.  Plasma membrane organization is essential for balancing competing pseudopod- and uropod-promoting signals during neutrophil polarization and migration.

Authors:  Stéphane Bodin; Matthew D Welch
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

5.  Molecular mechanisms of spontaneous and directed mast cell motility.

Authors:  Jinmin Lee; Sarah L Veatch; Barbara Baird; David Holowka
Journal:  J Leukoc Biol       Date:  2012-08-02       Impact factor: 4.962

Review 6.  Moving towards a paradigm: common mechanisms of chemotactic signaling in Dictyostelium and mammalian leukocytes.

Authors:  Yulia Artemenko; Thomas J Lampert; Peter N Devreotes
Journal:  Cell Mol Life Sci       Date:  2014-05-21       Impact factor: 9.261

Review 7.  PIP3, PIP2, and cell movement--similar messages, different meanings?

Authors:  R H Insall; O D Weiner
Journal:  Dev Cell       Date:  2001-12       Impact factor: 12.270

8.  Controlled pseudopod extension of human neutrophils stimulated with different chemoattractants.

Authors:  Doncho V Zhelev; Abdullatif M Alteraifi; David Chodniewicz
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Fer kinase limits neutrophil chemotaxis toward end target chemoattractants.

Authors:  Maitham Khajah; Graciela Andonegui; Ronald Chan; Andrew W Craig; Peter A Greer; Donna-Marie McCafferty
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.